Ancilia develops novel bacterial therapies that target the viral components of the microbiome to address chronic diseases across immunology and oncology indications. Our approach harnesses the natural function of CRISPR to enhance bacterial immunity against viruses and effectively modulate the human microbiome.
Employees: 1-10
Total raised: $4.2M
Founded date: 2019
Investors 2
| Date | Name | Website |
| 25.04.2023 | Metaplanet... | metaplanet... |
| - | Bioverge | ventures.b... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.08.2024 | - | $4.2M | - |
Mentions in press and media 2
| Date | Title | Description |
| 28.08.2024 | Ancilia Biosciences Closes $4.2M Financing | Ancilia Biosciences, Inc., a NYC-based biotechnology company using CRISPR to create bacterial therapies and products with immunity against destructive viruses, raised $4.2M in funding. The round was led by Safar Partners, with the participa... |
| - | Ancilia Biosciences | “A CRISPR route to success for live biotherapeutics & bacterial products” |